SpliceBio
Barcelona, Spain · Biotechnology, Science And Engineering, Software · 35 employees
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Ve
Funding history
- Series series b — $135.0M — Jun 2025
Recent signals
- Jan 06, 2026: SpliceBio Appoints Don Munoz as Chief Financial Officer
- Jun 11, 2025: Raised $135.0M in Series series b
- Jan 03, 2024: SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer
- Jun 20, 2023: SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program
See plans & pricing → Track SpliceBio’s funding, hiring, and signals — with verified contacts — on Fundz.